• Register
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.


Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.


Vif hijacks CBF-β to degrade APOBEC3G and promote HIV-1 infection.

Restriction factors, such as the retroviral complementary DNA deaminase APOBEC3G, are cellular proteins that dominantly block virus replication. The AIDS virus, human immunodeficiency virus type 1 (HIV-1), produces the accessory factor Vif, which counteracts the host's antiviral defence by hijacking a ubiquitin ligase complex, containing CUL5, ELOC, ELOB and a RING-box protein, and targeting APOBEC3G for degradation. Here we reveal, using an affinity tag/purification mass spectrometry approach, that Vif additionally recruits the transcription cofactor CBF-β to this ubiquitin ligase complex. CBF-β, which normally functions in concert with RUNX DNA binding proteins, allows the reconstitution of a recombinant six-protein assembly that elicits specific polyubiquitination activity with APOBEC3G, but not the related deaminase APOBEC3A. Using RNA knockdown and genetic complementation studies, we also demonstrate that CBF-β is required for Vif-mediated degradation of APOBEC3G and therefore for preserving HIV-1 infectivity. Finally, simian immunodeficiency virus (SIV) Vif also binds to and requires CBF-β to degrade rhesus macaque APOBEC3G, indicating functional conservation. Methods of disrupting the CBF-β-Vif interaction might enable HIV-1 restriction and provide a supplement to current antiviral therapies that primarily target viral proteins.

Pubmed ID: 22190037


  • Jäger S
  • Kim DY
  • Hultquist JF
  • Shindo K
  • LaRue RS
  • Kwon E
  • Li M
  • Anderson BD
  • Yen L
  • Stanley D
  • Mahon C
  • Kane J
  • Franks-Skiba K
  • Cimermancic P
  • Burlingame A
  • Sali A
  • Craik CS
  • Harris RS
  • Gross JD
  • Krogan NJ



Publication Data

January 19, 2012

Associated Grants

  • Agency: NIAID NIH HHS, Id: P01 AI090935
  • Agency: NIAID NIH HHS, Id: P01 AI090935
  • Agency: NIGMS NIH HHS, Id: P01 GM091743
  • Agency: NIGMS NIH HHS, Id: P41 GM103481
  • Agency: NCRR NIH HHS, Id: P41RR001614
  • Agency: NIGMS NIH HHS, Id: P50 GM081879
  • Agency: NIGMS NIH HHS, Id: P50 GM081879
  • Agency: NIGMS NIH HHS, Id: P50 GM082250
  • Agency: NIGMS NIH HHS, Id: P50 GM082250
  • Agency: NIGMS NIH HHS, Id: P50 GM082250-05
  • Agency: NIGMS NIH HHS, Id: P50GM081879
  • Agency: NIAID NIH HHS, Id: R01 AI064046
  • Agency: NIAID NIH HHS, Id: T32 AI083196
  • Agency: NCRR NIH HHS, Id: U54 RR022220

Mesh Terms

  • Affinity Labels
  • Animals
  • Core Binding Factor beta Subunit
  • Cullin Proteins
  • Cytidine Deaminase
  • Gene Knockdown Techniques
  • Gene Products, vif
  • Genetic Complementation Test
  • HEK293 Cells
  • HIV Infections
  • HIV-1
  • Host-Pathogen Interactions
  • Humans
  • Jurkat Cells
  • Macaca mulatta
  • Mass Spectrometry
  • Models, Biological
  • Protein Binding
  • Proteolysis
  • Simian immunodeficiency virus
  • Ubiquitin-Protein Ligases
  • Ubiquitination
  • Virus Replication
  • vif Gene Products, Human Immunodeficiency Virus